Novel Therapeutic Targeting in Cancer: An Interdisciplinary Approach

The “Novel Therapeutic Targeting in Cancer: An Interdisciplinary Approach” is the twenty sixth volume of the “Interdisciplinary Cancer Research” series, publishes comprehensive volume on novel therapeutic targeting in cancer. The volume starts with a chapter on telomere, DNA damage response, and nanomedicine, as a triad for cancer treatment innovation, followed by two general chapters on precision oncology and interdisciplinary pathways for cancer treatment. Advanced targeting systems for tissue-specific drug delivery and new-generation drug delivery systems as anticancer strategies are the subjects of the following chapters. After discussion on targeting inflammatory proteins for inhibition of cell proliferation in tumor microenviroment, small RNAs, microRNAs, as well as implementing CRISPR/Cas9 and microbiota genomics are explained. Targeting glycan, lectin-based targeted drug delivery systems, proteolysis targeting chimeras, dihydrofolate reductase inhibitors, PARP, ATR, RUVBL1/2 complex, and metal-coordination complexes in cancer treatment are explained in other chapters. Finally, computational advancements and in vitro evaluation in pre-clinical anticancer drug discovery and development are discussed in the last chapter. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value for those who wish to have an update on cancer therapeutic targeting.

Sommario

Telomere, DNA Damage Response, and Nanomedicine: A Triad for Cancer Treatment Innovation.- Precision Oncology: A Method to Maximize Quality of Life.- Interdisciplinary pathways for cancer treatment.- Advanced targeting systems for tissue-specific drug delivery.- New-Generation Drug Delivery Systems (DDSs) in Anticancer Strategies: Impact of Autophagy and Its Modulation.- Targeting Inflammatory Proteins for Inhibition of Cell Proliferation in Tumor Microenvironment.- Small RNAs in Cancer Therapy.- The dynamic interplay of immune cells, tumor cells, and miRNAs is a crucial focus in the search for new therapeutic targets.- Controlled Delivery of Target-Specific MicroRNA Analogs as a Key to RNAi Therapeutics in Cancer.- RNA Modifications as a Therapeutic Target in Gastrointestinal Cancer: Exploring Emerging Opportunities.- Implementing CRISPR/Cas9 into the study of anticancer drug resistance.- Microbiota Genomics and Cancer: Potential Role in Prediction as Tumor Markers, Diagnosis, and Response to Treatment.- Fighting cancer using selective antagonists targeting the substance P/neurokinin-1 receptor system.- Chronobiologically Targeted Anticancer Strategy: Synergistic Inhibition of CD39 and CD73 with Adenosine Receptor Agonists.- The sweet and sour of glycan targeting in cancer.- Lectin-based targeted drug delivery systems for the treatment of cancer.- PROTAC as an Innovative Drug Discovery Strategy for Cancer Treatment.- Dihydrofolate reductase inhibitors as anticancer agents: progress and perspectives in drug design and development.- PARP1: Opportunities of Developing New Drugs for an Old Target.- Therapeutic targeting of ATR in cancer.- RUVBL1/2 Complex in Cancer: Emerging Mechanisms and Therapeutic Opportunities.- Advances in Metal-Based Compounds as Emerging Therapeutics for Cancer Treatment.- New targets for cancer pain relief.- Computational Advancements and In Vitro Evaluation in Pre-Clinical Anticancer Drug Discovery and Development.

Info autore

Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital.  Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research and Technologies, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the Founder of Universal Scientific Education and Research Network (USERN). Prof. Rezaei has already been the Director of more than two hundred research projects and has designed and participated in several international collaborative projects. Prof. Rezaei is the editor, editorial assistant, or editorial board member of more than fifty international journals. He has edited more than one hundred international books, has presented more than a thousand lectures/posters in congresses/meetings, and has published more than 1,700 scientific papers in the international journals.

Riassunto

The “Novel Therapeutic Targeting in Cancer: An Interdisciplinary Approach” is the twenty sixth volume of the “Interdisciplinary Cancer Research” series, publishes comprehensive volume on novel therapeutic targeting in cancer. The volume starts with a chapter on telomere, DNA damage response, and nanomedicine, as a triad for cancer treatment innovation, followed by two general chapters on precision oncology and interdisciplinary pathways for cancer treatment. Advanced targeting systems for tissue-specific drug delivery and new-generation drug delivery systems as anticancer strategies are the subjects of the following chapters. After discussion on targeting inflammatory proteins for inhibition of cell proliferation in tumor microenviroment, small RNAs, microRNAs, as well as implementing CRISPR/Cas9 and microbiota genomics are explained. Targeting glycan, lectin-based targeted drug delivery systems, proteolysis targeting chimeras, dihydrofolate reductase inhibitors, PARP, ATR, RUVBL1/2 complex, and metal-coordination complexes in cancer treatment are explained in other chapters. Finally, computational advancements and in vitro evaluation in pre-clinical anticancer drug discovery and development are discussed in the last chapter. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value for those who wish to have an update on cancer therapeutic targeting.

Dettagli sul prodotto

• Con la collaborazione di: Nima Rezaei (Editore)
• Editore: Springer International Publishing
• Lingue: Inglese
• Formato: Copertina rigida
• Pubblicazione: 28.04.2026
• EAN: 9783032144003
• ISBN: 978-3-032-14400-3
• Pagine: 670
• Illustrazioni: X, 670 p. 82 illus., 67 illus. in color., farbige Illustrationen, schwarz-weiss Illustrationen
• Serie: Interdisciplinary Cancer Research
• Categorie: Scienze naturali, medicina, informatica, tecnica > Medicina > Branche non cliniche; Immunologie, Oncology, cancer therapy, Cancer Biology, Tumour Immunology, Immunotherapy, Tumor microenvironment, Cancer Nanotechnology, Cancer therapies, RUVBL1/2 Complex, Gastric cancers, Microbiota genomics